Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops

Sep 4, 2019

Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

Aug 7, 2019

Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials

Jul 22, 2019

Rexahn Announces Move to Nasdaq

May 28, 2019

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

May 13, 2019

Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China

Apr 16, 2019

Rexahn Effects 1-for-12 Reverse Stock Split

Apr 12, 2019

Rexahn Announces Reverse Stock Split

Apr 10, 2019

Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting

Mar 27, 2019

Rexahn Pharmaceuticals Reports 2018 Financial Results

Mar 8, 2019